Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer

NCT02005887 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT02005887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02005887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
August 25, 2017
Enrollment
51 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer invasive nos